The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice
- PMID: 10828883
- DOI: 10.1038/sj.onc.1203572
The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice
Abstract
The characteristic t(12;16)(q13;p11) chromosomal translocation, which leads to gene fusion that encodes the FUS-CHOP chimeric protein, is associated with human liposarcomas. The altered expression of FUS-CHOP has been implicated in a characteristic subgroup of human liposarcomas. We have introduced the FUS-CHOP transgene into the mouse genome in which the expression of the transgene is successfully driven by the elongation factor 1alpha (EF1alpha) promoter to all tissues. The consequent overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-specific genes and a concordant block in the differentiation program. We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARgamma, whereas it is not expressed in embryonic fibroblasts from these animals following induction to differentiation toward the adipocyte lineage, indicating that the in vitro system does not really reflect the in vivo situation and the developmental defect is downstream of PPARgamma expression. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1alpha promoter. This establishes FUS-CHOP overexpression as a key determinant of human liposarcomas and provide the first in vivo evidence for a link between a fusion gene created by a chromosomal translocation and a solid tumor.
Similar articles
-
Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma.Oncogene. 2000 Dec 7;19(52):6015-22. doi: 10.1038/sj.onc.1204018. Oncogene. 2000. PMID: 11146553
-
Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.Am J Pathol. 1995 Nov;147(5):1221-7. Am J Pathol. 1995. PMID: 7485386 Free PMC article.
-
FUS/TLS-CHOP chimeric transcripts in liposarcoma tissues.Jpn J Clin Oncol. 1995 Dec;25(6):234-9. Jpn J Clin Oncol. 1995. PMID: 8523819
-
Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model.Semin Cancer Biol. 2005 Jun;15(3):206-14. doi: 10.1016/j.semcancer.2005.01.006. Semin Cancer Biol. 2005. PMID: 15826835 Review.
-
[Current idea of the morphogenetic features of liposarcomas].Arkh Patol. 2012 Nov-Dec;74(6):61-3. Arkh Patol. 2012. PMID: 23383449 Review. Russian.
Cited by
-
FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.Biomolecules. 2024 Oct 14;14(10):1297. doi: 10.3390/biom14101297. Biomolecules. 2024. PMID: 39456230 Free PMC article. Review.
-
Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions.Cancers (Basel). 2021 May 13;13(10):2359. doi: 10.3390/cancers13102359. Cancers (Basel). 2021. PMID: 34068344 Free PMC article. Review.
-
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.PLoS One. 2008 Jul 2;3(7):e2569. doi: 10.1371/journal.pone.0002569. PLoS One. 2008. PMID: 18596980 Free PMC article.
-
Requirement for YAP1 signaling in myxoid liposarcoma.EMBO Mol Med. 2019 May;11(5):e9889. doi: 10.15252/emmm.201809889. EMBO Mol Med. 2019. PMID: 30898787 Free PMC article.
-
Modeling sarcomagenesis using multipotent mesenchymal stem cells.Cell Res. 2012 Jan;22(1):62-77. doi: 10.1038/cr.2011.157. Epub 2011 Sep 20. Cell Res. 2012. PMID: 21931359 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials